Mitch Sivilotti is a respected leader in the Life Sciences industry and serves as the President and Chief Executive Officer of OmniaBio Inc., a CDMO serving the cell and gene therapy market.
Most recently, Mitch was the Chief Operating Officer at CCRM, a Toronto-based cell and gene therapy (CGT) accelerator focused on cell therapy and viral vector manufacturing innovation, company creation and early-stage venture investments. Over the course of six years at CCRM, Mitch was responsible for creating a contract development and manufacturing organization with 200 employees, which grew to become OmniaBio Inc. Before joining CCRM, Mitch was the President of TotipotentRX Corporation, which designed and commercialized sterile disposables for the CGT market, and developed a therapeutic pipeline of candidates for cardiovascular diseases. Its lead product was granted pivotal trial approval in the U.S for Critical Limb Ischemia. TotipotentRX, co-founded by Mitch in 2007, was acquired by Thermogenesis Corporation (Nasdaq: THMO) in 2014. Mitch’s professional career began at Pall Corporation, a Danaher company (NYSE: DHR), where he held several business management and technical positions focused on process equipment and sterile consumables for the advanced therapies market.
Mr. Sivilotti sits on the board of the Standards Coordinating Body for Regenerative Medicine and is a regular contributor to the Forum on Regenerative Medicine at the National Academy of Sciences, where he has supported an ex-officio member seat for CCRM for four years.
Mr. Sivilotti holds a graduate degree in Cellular and Molecular Biology from the Université Laval (Quebec, Canada) and a graduate degree in Finance from Queen’s University (Kingston, Canada).